CECOG experts' recommendations on the use of denosumab in the prevention of skeletal-related events in bone metastases of lung cancer

Hilbe, Wolfgang; Abacioglu, Ufuk; Aebersold, Daniel M.; Bachouchi, Mounir; Brodowicz, Thomas; Gaafar, Rabab; Holzer, Gerold; Mohn-Staudner, Andrea; Kalev, Dimitar; Kalinka-Warzocha, Eva; Kovac, Viljem; Siano, Marco; Yumuk, Fulden; Tamasi, Lila (2013). CECOG experts' recommendations on the use of denosumab in the prevention of skeletal-related events in bone metastases of lung cancer. memo - Magazine of European Medical Oncology, 6(2), pp. 75-82. Springer 10.1007/s12254-013-0088-6

Full text not available from this repository. (Request a copy)


Skeletal-related events represent a substantial burden for patients with advanced cancer. Randomized, controlled studies suggested superiority of denosumab over zoledronic acid in the prevention of skeletal-related events in metastatic cancer patients, with a favorable safety profile. Experts gathered at the 2012 Skeletal Care Academy in Istanbul to bring forward practical recommendations, based on current evidence, for the use of denosumab in patients with bone metastases of lung cancer.

Based on current evidence, use of denosumab in lung cancer patients with confirmed bone metastases is recommended. It is important to note that clinical judgment should take into consideration the patient’s general performance status, overall prognosis, and live expectancy. Currently, the adverse event profile reported for denosumab includes hypocalcemia and infrequent occurrence of osteonecrosis of the jaw. Therefore, routine calcium and vitamin D supplementation, along with dental examination prior to denosumab initiation are recommended. There is no evidence for renal function impairment due to denosumab administration. At present, there is no rationale to discourage concomitant use of denosumab and surgery or radiotherapy.

Item Type:

Journal Article (Original Article)


04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Radiation Oncology

UniBE Contributor:

Aebersold, Daniel Matthias


600 Technology > 610 Medicine & health








Beatrice Scheidegger

Date Deposited:

23 Apr 2014 11:25

Last Modified:

02 Mar 2023 23:24

Publisher DOI:




Actions (login required)

Edit item Edit item
Provide Feedback